Longeveron Receives Nasdaq Extension to Regain Minimum Bid Price Compliance
LGVN has more than doubled off its 52-week low of $0.475 on light trading volume (0.1× avg).
Summary
Longeveron Inc. received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, pushing the deadline to September 21, 2026.
Key Events · Corporate Governance and Compliance · LGVN
-
Nasdaq Grants Listing Extension
Longeveron Inc. received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, setting a new deadline of September 21, 2026.
-
No Immediate Delisting
The notice confirms that there is no immediate effect on the company's continued listing status on The Nasdaq Capital Market.
-
Potential Reverse Stock Split
The company stated its intention to monitor its stock price and assess options, including a reverse stock split, if necessary, to regain compliance.
-
Ongoing Compliance Challenge
This follows an initial delisting notice on September 22, 2025, highlighting the company's persistent challenge in meeting Nasdaq's minimum bid price rule amidst broader financial concerns.
Analysis · LGVN · Life Sciences
Longeveron Inc. has been granted an additional 180 days by Nasdaq, extending its compliance period for the $1.00 minimum bid price requirement until September 21, 2026. This extension provides a temporary reprieve from immediate delisting, which is critical for a company that recently disclosed substantial doubt about its ability to continue as a going concern in its 10-K filing on March 17, 2026. While the extension avoids an immediate negative outcome, the company still faces the challenge of raising its stock price, potentially through a reverse stock split, to maintain its Nasdaq listing. This situation underscores the ongoing financial pressures and the need for strategic actions to ensure long-term viability, following a highly dilutive private placement in mid-March.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.6% of the 1742 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGVN was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $0.48 to $1.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.